Clinical Features and Treatment Outcome of Coronavirus and Tuberculosis Co-Infected Patients: A Systematic Review of Case Reports.
COVID-19
Mycobacterium tuberculosis
SARSCOV-2
TB
co-infection
coronavirus
tuberculosis
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
04
2022
accepted:
15
07
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
5
8
2022
Statut:
epublish
Résumé
Coronavirus disease 19 (COVID-19) and An electronic search of case reports published between 2020 and 2021 was conducted using Google Scholar, PubMed, Scopus, and ScienceDirect. From eligible reports, data were collected for the selected variables. We analyzed the collected information using SPSS version 27 software. Descriptive statistics were computed for the selected variables. A total of 83 patient histories were collected from 47 case reports. The majority (80%) of the cases were reported for male patients. The mean age was 42.6 years (3 months to 84 years, SD=17.3). Fever was reported in 80% of cases, followed by cough (73.3%) and hypotension (37.1%). Blood cell parameters revealed lymphopenia (52%), lower hemoglobin (30%), elevated CRP (70%), elevated ferritin (28%), and increased D-dimer (23.4%). Treatment outcome is significantly associated with blood cell count results ( An alteration in blood cell parameters is associated with an unfavorable treatment outcome. There is a higher death rate in COVID-19/TB co-infection. The death is associated with older age, smoking or smoking history, drug abuse, and co-morbidity of non-communicable diseases. Conversely, there is a lower death rate in HIV patients.
Sections du résumé
Background
UNASSIGNED
Coronavirus disease 19 (COVID-19) and
Methods
UNASSIGNED
An electronic search of case reports published between 2020 and 2021 was conducted using Google Scholar, PubMed, Scopus, and ScienceDirect. From eligible reports, data were collected for the selected variables. We analyzed the collected information using SPSS version 27 software. Descriptive statistics were computed for the selected variables.
Results
UNASSIGNED
A total of 83 patient histories were collected from 47 case reports. The majority (80%) of the cases were reported for male patients. The mean age was 42.6 years (3 months to 84 years, SD=17.3). Fever was reported in 80% of cases, followed by cough (73.3%) and hypotension (37.1%). Blood cell parameters revealed lymphopenia (52%), lower hemoglobin (30%), elevated CRP (70%), elevated ferritin (28%), and increased D-dimer (23.4%). Treatment outcome is significantly associated with blood cell count results (
Conclusion
UNASSIGNED
An alteration in blood cell parameters is associated with an unfavorable treatment outcome. There is a higher death rate in COVID-19/TB co-infection. The death is associated with older age, smoking or smoking history, drug abuse, and co-morbidity of non-communicable diseases. Conversely, there is a lower death rate in HIV patients.
Identifiants
pubmed: 35924015
doi: 10.2147/IDR.S370837
pii: 370837
pmc: PMC9342249
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
4037-4046Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Informations de copyright
© 2022 Mollalign et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in relation to this work.
Références
J Med Virol. 2021 Jan;93(1):194-196
pubmed: 32687228
BMC Pediatr. 2020 Sep 9;20(1):429
pubmed: 32907595
AIDS. 2020 Dec 1;34(15):2165-2168
pubmed: 32910070
SN Compr Clin Med. 2020;2(11):2419-2422
pubmed: 33103062
Eur Heart J Case Rep. 2020 Dec 28;5(1):ytaa491
pubmed: 33644650
Diabetes Res Clin Pract. 2020 Aug;166:108293
pubmed: 32623035
BMJ Case Rep. 2020 Sep 14;13(9):
pubmed: 32928816
Nat Immunol. 2021 Apr;22(4):404-411
pubmed: 33723418
J Clin Med. 2020 Jun 05;9(6):
pubmed: 32516940
Am J Trop Med Hyg. 2020 Oct;103(4):1593-1596
pubmed: 32815515
Oman Med J. 2021 Sep 28;36(5):e298
pubmed: 34631157
Respir Med Case Rep. 2021;32:101344
pubmed: 33495728
Front Public Health. 2020 May 28;8:216
pubmed: 32574299
J Clin Tuberc Other Mycobact Dis. 2021 Jan 07;22:100213
pubmed: 33521333
Am J Trop Med Hyg. 2020 Oct;103(4):1597-1599
pubmed: 32815513
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33945513
Am J Case Rep. 2020 Aug 19;21:e926034
pubmed: 32813683
Respir Investig. 2021 Mar;59(2):187-193
pubmed: 33281114
J Transl Int Med. 2020 Jun 25;8(2):59-65
pubmed: 32983927
J Infect Dev Ctries. 2020 Jul 31;14(7):721-725
pubmed: 32794460
Travel Med Infect Dis. 2021 Sep-Oct;43:102129
pubmed: 34174407
Case Rep Infect Dis. 2021 Jan 15;2021:8840536
pubmed: 33505740
J Community Health. 2020 Dec;45(6):1270-1282
pubmed: 32918645
Int J Infect Dis. 2022 Apr 26;:
pubmed: 35483555
J Infect. 2020 Sep;81(3):e39-e40
pubmed: 32610112
Indian J Crit Care Med. 2020 Nov;24(11):1132-1134
pubmed: 33384523
BMJ Case Rep. 2021 Apr 21;14(4):
pubmed: 33883111
Am J Emerg Med. 2021 Aug;46:16-19
pubmed: 33706251
Emerg Infect Dis. 2020 Nov;26(11):2755-2758
pubmed: 32667282
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34764184
Am J Trop Med Hyg. 2020 Nov;103(5):1986-1988
pubmed: 32978934
Pan Afr Med J. 2020 Aug 31;36:374
pubmed: 33235651
Tuberculosis (Edinb). 2021 Jan;126:102020
pubmed: 33246269
Clin Case Rep. 2021 May 24;9(5):e04233
pubmed: 34084515
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
JRSM Open. 2021 Feb 11;12(2):2054270420985736
pubmed: 33628454
Ann Med Surg (Lond). 2021 Jan 12;62:80-83
pubmed: 33505676
Pulmonology. 2020 Jul - Aug;26(4):233-240
pubmed: 32411943
Int J Mycobacteriol. 2021 Apr-Jun;10(2):206-209
pubmed: 34558477
Cureus. 2020 Nov 28;12(11):e11734
pubmed: 33403166
IDCases. 2020;22:e00973
pubmed: 33014710
J Intensive Care. 2020 May 24;8:36
pubmed: 32483488
Am J Case Rep. 2020 Nov 05;21:e927628
pubmed: 33151912
Front Public Health. 2020 Aug 13;8:473
pubmed: 32903584